These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18424323)

  • 21. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
    N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study.
    Colombo D; Cassano N; Altomare G; Giannetti A; Vena GA
    Int J Immunopathol Pharmacol; 2010; 23(4):1143-52. PubMed ID: 21244763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
    Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
    Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC
    J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
    Tyring S; Gottlieb A; Papp K; Gordon K; Leonardi C; Wang A; Lalla D; Woolley M; Jahreis A; Zitnik R; Cella D; Krishnan R
    Lancet; 2006 Jan; 367(9504):29-35. PubMed ID: 16399150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S; Krishna V; Kanwar AJ
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks.
    Sivanesan SP; Gattu S; Hong J; Chavez-Frazier A; Bandow GD; Malick F; Kricorian G; Koo J
    J Am Acad Dermatol; 2009 Nov; 61(5):793-8. PubMed ID: 19766350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial.
    David M; Akerman L; Ziv M; Kadurina M; Gospodinov D; Pavlotsky F; Yankova R; Kouzeva V; Ramon M; Silverman MH; Fishman P
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):361-7. PubMed ID: 21504485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
    Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J;
    Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study.
    Dogra S; Jain A; Kanwar AJ
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e305-11. PubMed ID: 22816881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
    Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
    Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.